

1 **Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19**
2 **vaccination**

3

4 Zhao-Hua Zhou^{1*}, Margaret M. Cortese^{2*}, Jia-Long Fang³, Robert Wood⁴, Donna S. Hummell⁵, Kimberly
5 A. Risma⁶, Allison E. Norton⁵, Mark KuKuruga⁷, Susan Kirshner¹, Ronald L. Rabin⁷, Cyrus Agarabi¹, Mary A.
6 Staat⁸, Natasha Halasa⁹, Russell Ware¹⁰, Anna Stahl⁹, Maureen McMahon⁸, Peter Browning¹¹, Panagiotis
7 Maniatis¹¹, Shanna Bolcen¹¹, Kathryn M. Edwards⁹, John R. Su², Sai Dharmarajan¹, Richard Forshee⁷,
8 Karen R. Broder², Steven Anderson⁷ and Steven Kozlowski¹

9

10 ¹Center for Drug Evaluation and Research and ⁷Center for Biologics Evaluation and Research, Food and
11 Drug Administration

12 ² Immunization Safety Office, Division of Healthcare Quality and Promotion, National Center for
13 Emerging and Zoonotic Infectious Diseases and ¹¹Microbial Pathogenesis and Immune Response
14 Laboratory, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases,
15 Centers for Disease Control and Prevention, Atlanta, GA

16 ³National Center for Toxicological Research, Jefferson, AR

17 ⁴Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD

18 ⁵Division of Pediatric Allergy, Immunology, and Pulmonary Medicine, and ⁹Division of Infectious
19 Diseases, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt
20 University School of Medicine, Nashville, TN

21 ⁶ Division of Allergy Immunology, ⁸Division of Infectious Disease and ¹⁰Division of Hematology,
22 Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

23 *Contributed equally

24

25

26 Corresponding Author: Steven Kozlowski, 10903 New Hampshire Avenue, Silver Spring, MD 20993; 301-
27 796-2046; steven.kozlowski@fda.hhs.gov

28

29 **Abstract word count: 293**

30 **Manuscript word count: 3502**

31

32 **Abstract:**

33 **Background:** The mechanism for anaphylaxis following mRNA COVID-19 vaccination has been widely
34 debated; understanding this serious adverse event is important for future vaccines of similar design. A
35 mechanism proposed is type I hypersensitivity (i.e., IgE-mediated mast cell degranulation) to excipient
36 polyethylene glycol (PEG). Using an assay that, uniquely, had been previously assessed in patients with
37 anaphylaxis to PEG, our objective was to compare anti-PEG IgE in serum from mRNA COVID-19 vaccine
38 anaphylaxis case-patients and persons vaccinated without allergic reactions. Secondly, we compared
39 anti-PEG IgG and IgM to assess alternative mechanisms.

40 **Methods:** Selected anaphylaxis case-patients reported to U.S. Vaccine Adverse Event Reporting System
41 December 14, 2020 – March 25, 2021 were invited to provide a serum sample. mRNA COVID-19 vaccine
42 study participants with residual serum and no allergic reaction post-vaccination (“controls”) were
43 frequency matched to cases 3:1 on vaccine and dose number, sex and 10-year age category. Anti-PEG
44 IgE was measured using a dual cytometric bead assay. Anti-PEG IgG and IgM were measured using two
45 different assays. Laboratorians were blinded to case/control status.

46 **Results:** All 20 case-patients were women; 17 had anaphylaxis after dose 1, 3 after dose 2. Thirteen
47 (65%) were hospitalized and 7 (35%) were intubated. Time from vaccination to serum collection was
48 longer for case-patients vs controls (post-dose 1: median 105 vs 21 days). Among Moderna recipients,
49 anti-PEG IgE was detected in 1 of 10 (10%) case-patients vs 8 of 30 (27%) controls ($p=0.40$); among
50 Pfizer-BioNTech recipients, it was detected in 0 of 10 case-patients (0%) vs 1 of 30 (3%) controls
51 ($p>0.99$). Anti-PEG IgE quantitative signals followed this same pattern. Neither anti-PEG IgG nor IgM was
52 associated with case status with both assay formats.

53 **Conclusion:** Our results support that anti-PEG IgE is not a predominant mechanism for anaphylaxis post-
54 mRNA COVID-19 vaccination.

55 **Key Words:** COVID 19; mRNA vaccines; polyethylene glycol; anaphylaxis; IgE; antibodies

56

57

58 INTRODUCTION

59 Soon after the introduction of mRNA COVID-19 vaccines in adults in December 2020 in the United
60 Kingdom and the United States, cases of anaphylaxis were reported, raising concerns that rates were
61 higher than seen with other vaccines.[1] In the United States, reporting rates for anaphylaxis from the
62 Vaccine Adverse Event Reporting System (VAERS) data through January 18, 2021 were estimated as 4.7
63 cases per million Pfizer-BioNTech vaccine doses administered and 2.5 cases per million Moderna vaccine
64 doses administered.[2, 3] From the Vaccine Safety Datalink (VSD), a collaboration between CDC and 9
65 integrated healthcare plans with a covered population of ~12 million people, the estimated rates of ~5
66 cases per million doses for each of the vaccine products through May 2021 appeared somewhat higher
67 than previous estimates from this system for trivalent inactivated influenza vaccine (the vaccine with the
68 largest number of doses administered in the VSD evaluation), 1.35 cases of anaphylaxis per million doses
69 administered.[4, 5]

70 Identifying the mechanism for anaphylaxis following mRNA COVID-19 vaccines is important because
71 several doses are needed for optimal protection, likely including repeated boosters and mRNA
72 technology is expected to be used in vaccines targeting other infectious diseases. One component
73 shared by both mRNA COVID-19 vaccine lipid nanoparticles (LNP) is polyethylene glycol (PEG) .[6, 7] PEG
74 has been previously identified as a potential allergen in medication reactions and thus was considered
75 the potential cause of the post-mRNA COVID-19 vaccine anaphylaxis.[1, 8] Proposed alternatives to anti-
76 PEG IgE-mediated type 1 hypersensitivity have included complement activation-related pseudoallergy
77 (CARPA, which could involve IgG or IgM antibodies, with PEG as one of the proposed antigens), and
78 direct mast cell effects through mRNA or other vaccine components.[9-13]

79 Detecting anti-PEG IgE among patients who had anaphylaxis after mRNA COVID-19 vaccination could
80 identify the allergen and mechanism of these reactions. Given that individuals with a history of

81 anaphylaxis to PEG-containing medications had been confirmed by the presence of anti-PEG IgE,[14] we
82 anticipated that detection of anti-PEG IgE in serum of patients after anaphylaxis from mRNA COVID-19
83 vaccines, and not in controls, would be an indicator of its relevance. There are no widely available
84 clinical tests for anti-PEG IgE. The accurate detection and quantitation of anti-PEG antibodies is
85 challenging as many assay formats have high background signals and lack specificity.[15] As low levels of
86 anti-PEG IgE may have clinical consequences, assays for anti-PEG IgE require greater sensitivity and
87 specificity than currently possible with most assay formats. Recently a bead-based cytometry assay with
88 internal control beads to subtract background signals was able to detect and determine titers of anti-
89 PEG IgE in patients with PEG-associated anaphylaxis.[14] We used this assay to evaluate case-patients
90 who had anaphylaxis after mRNA COVID-19 vaccination and control groups. Anti-PEG IgG and IgM were
91 also evaluated using two different assay formats.

92

93 **METHODS**

94 ***Case Identification and Controls***

95 We identified potential cases of anaphylaxis after mRNA COVID-19 vaccination, obtained and reviewed
96 medical records, and adjudicated cases with allergists from the Clinical Immunization Safety Assessment
97 (CISA) Project[16] to identify those most clinically consistent with anaphylaxis. Potential cases were
98 identified through 1) searches of the passive Vaccine Adverse Event Reporting System (VAERS)[17] for
99 reports coded as “anaphylaxis” or “anaphylactic reaction” after mRNA COVID-19 vaccination in persons
100 aged ≥ 18 years received during December 14, 2020–March 25, 2021, and by reviews for anaphylaxis
101 described in VAERS reports before coding, and 2) inquiries from healthcare providers or health
102 departments to CISA. VAERS reporting for such cases was encouraged. We excluded patients with an
103 underlying illness that could result in possible anaphylaxis (e.g. recurrent idiopathic anaphylaxis). We
104 also classified cases by 2007 Brighton Collaboration anaphylaxis case definition levels 1- 3; level 1 is the
105 highest level of diagnostic certainty.[18, 19] Based on feasibility, our goal was to enroll ≥ 10 case-patients

106 who had received Pfizer-BioNTech (“Pfizer-BioNTech case-patients”) and ≥ 10 who had received
107 Moderna (“Moderna case-patients”). Case-patients were contacted via telephone and sent a project
108 information sheet; those interested in participating provided a serum sample that was shipped to CDC
109 laboratory. Serum was collected ≥ 6 weeks after anaphylaxis to avoid the theoretical possibility that
110 allergen-specific serum IgE may have been reduced during the first few weeks after anaphylaxis.

111 Controls were selected from participants in unrelated post-authorization mRNA COVID-19 vaccine
112 studies at 2 CISA medical centers who had serum collected under their original study protocol, provided
113 consent for secondary use of residual serum, and for whom the specific COVID-19 vaccine dose (dose 1
114 vs 2) had been tolerated without allergic reaction. Serum from Pfizer-BioNTech recipients were obtained
115 from a Vanderbilt University study [“Pfizer-BioNTech controls”], and serum from Moderna recipients
116 [“Moderna controls”], from a Cincinnati Children’s Hospital Medical Center study. Controls were
117 frequency matched to case-patients 3:1, by vaccine manufacturer, post-vaccine dose number (dose 1 or
118 2), self-identified sex and age category (10-year intervals). A control could be selected only once (i.e., to
119 provide post-dose 1 or post-dose 2 serum). Serum provided from Pfizer-BioNTech controls had been
120 collected ~ 21 days after dose 1 (and before dose 2, if provided) and ~ 21 days after dose 2; from
121 Moderna controls, serum had been collected ~ 28 days after dose 1 (and before dose 2, if provided) and
122 ~ 35 days after dose 2.

123 ***Sample Handling and Ethics***

124 All serum samples were first shipped to a CDC laboratory. Testing was performed in two independent
125 laboratories. For shipment to each of the testing laboratories, separate aliquots were made and labelled
126 with unique specimen IDs so that laboratories were blinded to case/control status and vaccine
127 manufacturer.

128 This activity was reviewed by CDC and FDA in accordance with applicable regulations and institutional
129 policies and was deemed not to be research, per 45 C.F.R.§ 46.102(l)(2), and it was determined not to be
130 a clinical investigation as defined in 21 CFR part 56. IRB approval and formal informed consent
131 procedures were not required.

132 ***Anti-PEG IgE Assay***

133 Samples were evaluated for anti-PEG IgE in the laboratory of Office of Biotechnology Products (OBP),
134 Center for Drug Evaluation and Research (CDER), FDA using a Dual Cytometric Bead Assay (DCBA).[14]
135 Briefly, the samples were diluted 1:5 and incubated with target beads coated with PEGylated antigen
136 and controls beads without PEG. After washing the beads, a labeled antibody to human IgE was added.
137 After incubation and washing, the beads were analyzed by flow cytometry. The difference in median
138 fluorescence intensity (MFI) between the target and control beads was used to determine anti-PEG IgE
139 antibody positivity. The assay in the current study was qualified to be specific and sensitive enough to
140 detect ≤ 200 pg/mL anti-PEG IgE using a commercial anti-PEG IgE as a standard.

141 A cut-point for assay positivity was determined using a separate set of pre-existing sera (negative panel).
142 These sera were commercially sourced deidentified samples used in a prior study[14] and tested
143 negative. The negative panel and anti-PEG IgE standard run were repeated for assay consistency with
144 three preparations of target and control beads used in the current project. For the primary objective,
145 the cut-point was defined to be the average signal of the negative panel of pre-existing sera plus three
146 standard deviations (SD). A sensitivity analysis was performed with a 2-SD cut-point. Examples of anti-
147 PEG IgE assay quantitative signals are included in Supplementary Materials from the negative panel
148 (Figure S1A) and our participant samples (Figure S1B).

149 A positive IgE result for a sample was defined as a signal (MFI) that is greater than the pre-defined cut-
150 point value in two determinations and that can be inhibited by greater than 30% with the addition of

151 free pegfilgrastim at 5 mcg/ml (demonstrating PEG specificity). Although there were positive samples
152 based on the criteria, all of the signals were at the low end of the assay dynamic range, well below 1
153 ng/mL and lower than a prior sample from a patient with PEG allergy (Supplementary Figure S2).
154 Additional details are in Supplementary Materials.

155 ***Anti-PEG IgG and IgM assays***

156 Anti-PEG IgG and IgM were each evaluated by flow cytometry using two different platforms in two
157 different laboratories. The laboratories were blinded to each other's results as well as to sample case vs.
158 control status to minimize bias. The two assay platforms were the Dual Cytometric Bead Assay (DCBA)
159 and a PEGylated Polystyrene Beads Assay (PPBA) that used commercially available PEGylated beads
160 (TentaGel™ M OH beads). The DCBA was performed in OBP, CDER. The PPBA was performed in the
161 laboratory of National Center for Toxicological Research (NCTR).

162 For the anti-PEG IgG and IgM DCBA, similar to the anti-PEG IgE assay above, labeled antibodies to
163 human IgG and IgM were added after the sample incubation and washing. The titer was defined as the
164 highest dilution of sera that led to a 100% increase in signal over the control beads. A positive result was
165 defined as a titer of $\geq 1:20$. Examples of sample titrations for the IgG dual bead method are in
166 Supplementary Figure S2.

167 For the PPBA,[20] the beads were incubated with human samples diluted in 5% BSA, washed and stained
168 for bound IgG or IgM with a specific fluorescence conjugated anti-human IgG or IgM secondary
169 antibody, washed and analyzed by flow cytometry. The MFI was used to determine the presence or
170 absence of anti-PEG antibodies. The cut-point for sample positivity is equal to the MFI of the negative
171 controls (5% BSA) of each experiment plus 3 SD. The samples were also diluted, and the titer was
172 defined as the highest dilution of sera that exceeded the cut-point for positivity.

173 ***Statistical analysis***

174 Fisher's exact test was used to compare the proportion of case-patients vs controls positive for the
175 specific anti-PEG antibody isotype (IgE, IgG, IgM), for both vaccine manufacturers combined, and for
176 each vaccine separately. A p -value $< .05$ was considered statistically significant. The IgG and IgM results
177 were assessed separately for each testing platform. No adjustment was made for multiple comparisons.

178 We compared the differences between means of anti-PEG IgE signal intensity of the case-patient,
179 control and negative panel groups using the Tukey Kramer test. We determined the correlation between
180 anti-PEG IgG results from the two assays using all case-patients and controls combined using linear
181 regression for titers and percent concordance for positivity (Supplementary Figure S3 and Table S1). The
182 correlation between anti-PEG IgE (positive vs negative) and anti-PEG IgG titer was assessed using
183 Wilcoxon rank sum test. The correlation between anti-PEG IgM (positive vs negative) and anti-PEG IgG
184 titer was similarly assessed. Analyses were performed with JMP 16 (SAS Institute, Inc. Cary, NC) and
185 Stata 15 (College Station, TX).

186 **RESULTS**

187 ***Case enrollment and timing of serum sample collection***

188 Consistent with the initial reports of allergic reactions occurring primarily in female healthcare workers,
189 all case-patients selected to be approached for enrollment were female. Of the 25 case-patients that
190 were reached by telephone and were provided study information, 20 participated, 1 wished to
191 participate but was ineligible because of an underlying condition, 2 declined and for 2 follow-up calls
192 were not returned.

193 The median age of the Pfizer-BioNTech and Moderna case-patients was 40.5 years and 46.5 years,
194 respectively (Table 1). Seventeen case-patients had anaphylaxis after dose 1 and 3 after dose 2. All had
195 onset of symptoms ≤ 15 minutes post-vaccination. In total, 13 of 20 (65%) were admitted to the hospital
196 and 7 of 20 (35%) were intubated (**Table 1**).

197 Among Pfizer-BioNTech recipients in the post-dose 1 comparison, median number of days from dose to
198 sample collection was 105 for case-patients and 21 for controls (Supplementary Materials Table S2).
199 Among Moderna post-dose 1 recipients, median days to sample collection was 107 vs 26 for case-
200 patients vs controls, respectively. While receipt of dose 2 mRNA COVID-19 vaccine was not considered
201 during selection of post-dose 1 controls, all controls who had contributed post-dose 1 serum had shortly
202 thereafter received dose 2 without allergic reaction (one had mild asthma exacerbation within 4 weeks
203 post-dose 2—exact onset unknown—which she considered unlikely related to vaccination).

204 ***Anti-PEG IgE Results***

205 Using the 3-SD cut-point for positivity, with recipients of either vaccine combined, 1 of 20 (5%) case-
206 patients and 9 of 60 (15%) controls were positive for anti-PEG IgE ($p=0.44$) (**Table 2**). Among Moderna
207 recipients, the proportion positive tended to be higher among controls vs case-patients: 8 of 20 (27%)
208 controls vs 1 of 10 (10%) case-patients were positive ($p = .40$). Among Pfizer-BioNTech recipients, a
209 single control (1 of 30, 3%) and no cases (0 of 10; 0%) were anti-PEG IgE positive ($p>.99$) (**Table 2**).
210 Results were similar when stratified by first or second vaccine doses (Supplementary Table S3).
211 Results were in the same direction when the 2-SD cut-point was used in the sensitivity analysis, with
212 additional samples IgE positive among controls and case-patients. For recipients of either vaccine
213 combined, 17 of 60 (28%) controls and 2 of 20 (10%) case-patients were anti-PEG IgE positive ($p=.13$)
214 (**Table 2**). As with the 3-SD cut-off, the proportion positive tended to be higher among Moderna controls
215 vs Moderna case-patients (14 of 30 [47%] vs 1 of 10 [10%], $p=.06$). For Pfizer-BioNTech recipients,
216 positivity using a 2-SD cutoff was 10% for both controls (3 of 30) and case-patients (1 of 10) ($p>.99$).
217 With a pattern similar to that of the proportion anti-PEG IgE positive using the cut-point criteria, the
218 anti-PEG IgE quantitative signals (comparing MFI) were statistically significantly higher for controls vs
219 case-patients among Moderna recipients, and for these controls vs the negative panel samples

220 (Supplemental Figure S5). Among Pfizer-BioNTech recipients, there were no statistically significant
221 differences in the quantitative anti-PEG IgE signals for case-patients vs controls, nor each group vs the
222 negative panel samples.

223 In post-hoc unmatched comparison of controls by vaccine manufacturer, the proportion of Moderna
224 controls anti-PEG IgE positive was statistically significantly higher compared with that of Pfizer-BioNTech
225 controls (using 3-SD cut-point, 27% vs 3%, $p=.03$, using 2-SD cut-point 47% vs 10%, $p=.003$, respectively)

226 **(Table 2)**

227 ***Anti-PEG IgG and IgM Results***

228 The proportion of samples anti-PEG IgG positive was higher in control vs case-patients for recipients of
229 either vaccine (DCBA: 52% vs. 20%, $p = 0.014$; PPBA: 55% vs. 45%, $p = 0.45$) and for recipients of
230 Moderna vaccine (DCBA: 67% vs. 20%, $p = 0.003$; PPBA: 67% vs. 40%, $p = 0.16$), although the differences
231 were statistically significant only with DCBA **(Table 3)**. Among Pfizer-BioNTech recipients, with each
232 assay, the proportion of controls vs case-patients anti-PEG IgG positive was similar (~30-50%) **(Table 3)**.
233 The general pattern is similar to that observed with the anti-PEG IgE evaluation.

234 For anti-PEG IgM using DCBA, a relatively low proportion of participants were positive with no
235 statistically significant differences in case-patients vs controls among Moderna recipients nor among
236 Pfizer-BioNTech recipients **(Table 3)**. There tended to be a higher proportion of participants who were
237 anti-PEG IgM positive by PPBA compared with DCBA. With PPBA, among Pfizer-BioNTech recipients,
238 anti-PEG IgM positivity was higher in case-patients vs controls (6 of 10 (60%) vs 6 of 30 (20%), $p=.04$)
239 **(Table 3)**.

240 With both assays, the anti-PEG IgG titers correlated with the anti-PEG IgE result (Supplementary Figure
241 S6), with IgE-positive participants having higher IgG titers (for each assay, $p<.001$). Within each assay

242 type, the anti-PEG IgG titers also correlated with the anti-PEG IgM result, with IgM-positive participants
243 having higher IgG titers (for each assay type, $p < .001$).

244 In post-hoc comparison of groups by vaccine manufacturer, with DCBA, the proportion of Moderna
245 controls anti-PEG IgG-positive was statistically significantly higher compared with Pfizer-BioNTech
246 controls (**Table 3**). With both assay types, anti-PEG IgM positivity was statistically significantly higher in
247 Moderna controls vs Pfizer-BioNTech controls. Actual anti-PEG IgG titers were higher among Moderna
248 controls vs case-patients, but this was not observed for Pfizer-BioNTech recipients (Supplementary
249 Figure S7). Anti-PEG IgG and IgM titers in Moderna controls were higher than those in Pfizer-BioNTech
250 controls.

251 **DISCUSSION**

252 IgE-mediated hypersensitivity is a potential mechanism for the observed mRNA COVID-19 vaccine
253 anaphylaxis and PEG has been a suspected allergen. In our project with 20 patients with clinical
254 anaphylaxis post-mRNA COVID-19 vaccination and 60 matched controls who tolerated vaccination
255 without allergic reactions, only 1 case-patient had detectable anti-PEG IgE antibodies using a sensitive
256 assay and there was no positive correlation between anaphylaxis case status and anti-PEG IgE antibody
257 positivity. This was true when Moderna and Pfizer-BioNTech COVID-19 vaccine recipients were analyzed
258 together, or when evaluating each vaccine individually.

259 Our results support that pre-existing anti-PEG IgE is not the mechanism for many post-mRNA COVID-19
260 vaccine anaphylaxis cases and is consistent with other studies and clinical observations. Additionally, the
261 presence of anti-PEG IgE in some of our controls post-dose 1 (all of whom subsequently tolerated dose
262 2) suggests that the levels detected in our project were not clinically relevant. Warren et al[21]
263 evaluated anti-PEG IgE with an ELISA assay in serum of 12 patients who met Brighton anaphylaxis
264 criteria 1 or 2 (8 after Pfizer-BioNTech, 4 after Moderna) and none tested positive. Additional patients

265 with immediate non-anaphylactic allergic reactions and the 3 controls assessed (2 post Pfizer-BioNTech,
266 1 post Moderna) were also anti-PEG IgE negative. Anti-PEG IgE was not detected in a patient described
267 as having had a severe allergic reaction requiring hospitalization following mRNA COVID-19
268 vaccination.[22] However, Mouri et al[23] detected anti-PEG IgE using an ELISA assay in a patient with
269 Brighton level 3 anaphylaxis after Pfizer-BioNTech vaccination, as well as in other patients with
270 immediate non-anaphylactic and delayed reactions following mRNA COVID-19 vaccines. In their study,
271 anti-PEG IgE levels in the immediate reaction group were higher than in the control group (all Pfizer-
272 BioNTech recipients); some controls were anti-PEG IgE positive. Differences in anti-PEG assays are likely
273 a key reason for disparity among some reports; populations and classification of reactions may also
274 contribute. Importantly, there are several reports describing patients with anaphylaxis or suspected
275 anaphylaxis following first dose of mRNA COVID-19 vaccines who subsequently tolerated a second dose
276 without a serious allergic reaction.[24, 25] These patients had been carefully evaluated and monitored;
277 many were pre-medicated for the second dose and received it with graded administration. A larger
278 number of patients have been reported who had immediate, non-anaphylactic suspected allergic
279 reactions following a first mRNA COVID-19 vaccine and subsequently received a second dose without a
280 serious reaction.[24, 26] These reports of dose 2 tolerance support that at least some anaphylaxis cases
281 are due to mechanisms other than typical IgE-mediated type 1 hypersensitivity, regardless of the exact
282 allergen. Four anti-PEG IgE-positive patients in Mouri et al had also received a second dose of mRNA
283 COVID-19 vaccine, and all tolerated without allergic reaction.

284 We also did not find a positive correlation between cases and anti-PEG IgG positivity or titers; however,
285 anti-PEG IgM positivity was higher in case-patients than controls for Pfizer-BioNTech recipients only with
286 the PPBA assay (60% vs 20%, $p=.04$ without adjusting for multiple comparisons). In contrast to our anti-
287 PEG IgG findings, Warren et al detected anti-PEG IgG in 10 of 11 anaphylaxis case-patients but in none of
288 the 3 controls. The difference in assays may be key. Additionally, Warren et al case-patient samples

289 were collected sooner after anaphylaxis (median 36.5 days, range 0-78) than ours (median 105 days).
290 Their lower proportion of systemic corticosteroid receipt (4 of 12, 33% vs our 20 of 20, 100%) may have
291 also possibly contributed. Our control group was larger—30 per vaccine—and with samples collected a
292 median of ~21 days post-vaccination, we detected anti-PEG IgG in 37% – 67% depending on vaccine and
293 assay. Lim et al reported higher levels of anti-PEG IgG or anti-PEG IgM (anti-PEG IgE not evaluated) in 2
294 of 3 patients with suspected anaphylaxis from Pfizer-BioNTech vaccine vs controls.[27]

295 We found some differences by vaccine type. Moderna controls tended to have higher frequency and
296 signal intensity of anti-PEG IgE compared with Moderna case-patients or Pfizer-BioNTech controls.
297 Moderna controls had a higher frequency of anti-PEG IgG (DCBA) and IgM (both assays) than Pfizer-
298 BioNTech controls. Moderna controls also had higher titers of anti-PEG IgG and IgM than Pfizer-
299 BioNTech controls with both assay formats. Other studies have reported boosting of anti-PEG IgG in
300 Moderna vs Pfizer-BioNTech recipients who tolerated vaccination.[22, 28]

301 Strengths of our evaluation include cases selected from reports to national VAERS and CISA
302 infrastructures and adjudicated by CISA allergists, matched controls at a 3:1 ratio, blinding of samples,
303 and use of two independent assays when feasible. Limitations include case-patient sample size based on
304 feasibility. As with all such retrospective case reviews, particularly if tryptase was not measured during
305 the recommended period to aid in the assessment, it is possible that at least some of our cases were not
306 anaphylaxis. Most of our case-patients were treated promptly with epinephrine which may have
307 ameliorated severity. However, anaphylaxis can be very challenging to differentiate from other
308 immediate non-allergic reactions, including vocal cord dysfunction, immunization stress-related
309 response, and vasovagal reactions.[29-31] The shorter time to sample collection among our controls vs
310 case-patients may explain the higher frequencies and titers for some anti-PEG “non-mechanistic”
311 antibodies; the receipt of corticosteroids by all our cases may also have contributed. Other possible

312 limitations include assay performance, the nature of the PEG antigen (e.g., PEGylated lipids)[32] and
313 mast-cell associated anti-PEG antibodies not being reflected in serum levels.

314 Although we cannot exclude typical anti-PEG IgE-mediated type 1 hypersensitivity as a mechanism for
315 mRNA COVID-19 vaccine anaphylaxis, these results add further doubt as to this being the predominant
316 mechanism.

Acknowledgments. We would like to acknowledge the efforts of Laura Youngblood, MPH and Tom Shimabukuro, MD, MPH (CDC, Atlanta, GA), Pollyanna Stewart, MSN, RN-BC (Alaska Department of Health, Anchorage, AK), Juventila Liko, MPH and Paul Cieslak, MD (Oregon Public Health Division, Portland, OR), Frederick Little, MD (Boston Medical Center, Boston, MA), Joshua Milner, MD, PhD (Columbia University Irving Medical Center, New York, NY), Rendie McHenry, Joan Eason, Marcia Blair, and Danya Waqfi (Vanderbilt University School of Medicine), all the hospital and public health staff who assisted with sample collection, and all the participants who were willing to take part in this project.

Financial support. This work was supported by the Centers for Disease Control and Prevention Clinical Immunization Safety Assessment (CISA) Project contracts 200-2012-53661 to Cincinnati Children's Hospital Medical Center, 200-2012-50430 to Vanderbilt University Medical Center and 200-2012-53664 to Johns Hopkins University.

Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or the FDA. Mention of a product or company name is for identification purposes only and does not constitute endorsement by the CDC or the FDA.

Conflict of Interest Statements.

Donna S. Hummel: eDMC monitoring clinical trial (Merck)

Mary A. Staat: funding from NIH, CDC, Pfizer and Merck and royalties from UPToDate

Kathryn M. Edwards: Grant funding from NIH and CDC; Consultant to Bionet and IBM; Member Data Safety and Monitoring Board for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, Roche, Novavax, Brighton Collaboration

The other authors have no conflicts of interest.

References

- [1] Kelso JM. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines. *Vaccine*. 2021;39:865-7.
- [2] Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. *J Allergy Clin Immunol Pract*. 2021;9:3546-67.
- [3] Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. *JAMA*. 2021;325:1101-2.
- [4] Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. *JAMA*. 2021;326:1390-9.
- [5] McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunol*. 2016;137:868-78.
- [6] FDA. COMIRNATY Information with Package Inserts. 2022.
- [7] FDA. SPIKEVAX Information with Package Insert. 2022.
- [8] Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? *Br J Anaesth*. 2021;126:e106-e8.
- [9] Kelso JM. IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines. *Clin Exp Allergy*. 2022;52:10-1.
- [10] Cabanillas B, Akdis CA, Novak N. COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?". *Allergy*. 2021;76:1938-40.
- [11] Risma KA. COVID-19 mRNA vaccine allergy. *Curr Opin Pediatr*. 2021;33:610-7.
- [12] Risma KA, Edwards KM, Hummell DS, Little FF, Norton AE, Stallings A, et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. *J Allergy Clin Immunol*. 2021;147:2075-82 e2.
- [13] Balz K, Kaushik A, Chen M, Cemic F, Heger V, Renz H, et al. Homologies between SARS-CoV-2 and allergen proteins may direct T cell-mediated heterologous immune responses. *Sci Rep-Uk*. 2021;11.
- [14] Zhou ZH, Stone CA, Jakubovic B, Phillips EJ, Sussman G, Park J, et al. Anti-PEG IgE In Anaphylaxis Associated with Polyethylene Glycol. *J Allergy Clin Immunol Pract*. 2020.
- [15] Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. *Pharm Res*. 2013;30:1729-34.
- [16] CDC. Clinical Immunization Safety Assessment (CISA) Project. 2023.
- [17] Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). *Vaccine*. 2015;33:4398-405.
- [18] Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B, Brighton Collaboration Working Group on A. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. *Vaccine*. 2010;28:4487-98.
- [19] Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25:5675-84.
- [20] Fang JL, Beland FA, Tang Y, Roffler SR. Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma. *Toxicol Rep*. 2021;8:148-54.
- [21] Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, et al. Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. *JAMA Netw Open*. 2021;4:e2125524.

- [22] Carreno JM, Singh G, Tcheou J, Srivastava K, Gleason C, Muramatsu H, et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. *Vaccine*. 2022;40:6114-24.
- [23] Mouri M, Imamura M, Suzuki S, Kawasaki T, Ishizaki Y, Sakurai K, et al. Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines. *Allergol Int*. 2022;71:512-9.
- [24] Krantz MS, Kwah JH, Stone CA, Jr., Phillips EJ, Ortega G, Banerji A, et al. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. *JAMA Intern Med*. 2021;181:1530-3.
- [25] Chu DK, Abrams EM, Golden DBK, Blumenthal KG, Wolfson AR, Stone CA, Jr., et al. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis. *JAMA Intern Med*. 2022;182:376-85.
- [26] Tuong LC, Capucilli P, Staicu M, Ramsey A, Walsh EE, Shahzad Mustafa S. Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose. *Open Forum Infect Dis*. 2021;8:ofab507.
- [27] Lim XR, Leung BP, Ng CYL, Tan JWL, Chan GYL, Loh CM, et al. Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination. *Vaccines (Basel)*. 2021;9.
- [28] Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, et al. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. *ACS Nano*. 2022;16:11769-80.
- [29] Gold MS, MacDonald NE, McMurtry CM, Balakrishnan MR, Heininger U, Menning L, et al. Immunization stress-related response - Redefining immunization anxiety-related reaction as an adverse event following immunization. *Vaccine*. 2020;38:3015-20.
- [30] Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. *Ann Allergy Asthma Immunol*. 2021;127:133-4.
- [31] Leong P, Al-Harrasi M, Carr B, Leahy E, Bardin PG, Barnes S. Vocal cord dysfunction/inducible laryngeal obstruction(s) mimicking anaphylaxis during SARS-CoV-2 (COVID-19) vaccination. *J Aller Clin Imm-Pract*. 2022;10:1380-1.
- [32] Troelnikov A, Perkins G, Yuson C, Ahamdie A, Balouch S, Hurtado PR, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. *J Allergy Clin Immunol*. 2021;148:91-5.

Table 1. Selected features of anaphylaxis case-patients*

Characteristic	Total case-patients, n (%) N=20	Pfizer-BioNTech recipients, n (%) N=10	Moderna recipients, n (%) N=10
Female sex (self-identified)	20 (100)	10 (100)	10 (100)
Age, median, yrs (IQR) range	43.6 (36, 52) 28–57	40.5 (32, 52) 39–57	46.5 (39, 52) 28–54
Post dose 1	17 (85)	9 (90)	8 (80)
Post dose 2	3 (15)	1 (10)	2 (20)
Onset ≤15 minutes post-vaccination	20 (100)	10 (100)	10 (100)
Managed in ED only	7 (35)	5 (50)	2 (20)
Admitted to hospital or observed ≥1 night	13 (65)	5 (50)	8 (80)
Intubated	7 (35)	2 (20)	5 (50)
Treatment included:			
Epinephrine (IM or IV)	20 (100)	10 (100)	10 (100)
Epinephrine infusion	7 (35)	3 (30)	4 (40)
Systemic corticosteroids	20 (100)	10 (100)	10 (100)
Brighton level			
Level 1	14 (70)	7 (70)	7 (70)
Level 2	6 (30)	3 (30)	3 (30)

ED, emergency department

*Only 2 patients had tryptase measured in serum collected <24 hours after onset of reaction (one 2.75 hours after onset; one 7 hours after onset; both <5.5 ng/ml)

Table 2. Comparison of Anti-PEG IgE Positivity in Case-patients and Controls^a

Category	3 SD Threshold for Positivity			2 SD Threshold for Positivity		
	Case-	Controls	P-value	Case-	Controls	P-value
	patients	n (%)		patients	n (%)	
Recipients of either vaccine			0.44			0.13
Anti-PEG IgE positive	1 (5)	9 (15)		2 (10)	17 (28)	
Anti-PEG IgE negative	19 (95)	51 (85)		18 (90)	43 (72)	
Total	20	60		20	60	
Moderna vaccine recipients			0.40			0.06
Anti-PEG IgE positive	1 (10)	8 (27) ^b		1 (10)	14 (47) ^c	
Anti-PEG IgE negative	9 (90)	22 (73) ^b		9 (90)	16 (53) ^c	
Total	10	30		10	30	
Pfizer-BioNTech vaccine recipients			>.99			>.99
Anti-PEG IgE positive	0 (0)	1 (3) ^d		1 (10)	3 (10) ^e	
Anti-PEG IgE negative	10 (100)	29 (97) ^d		9 (90)	27 (90) ^e	
Total	10	30		10	30	

^aPositivity is based on a signal greater than 3 SD above the negative panel average in two determinations and 30% inhibition by PEG-filgrastim. A sensitivity analysis with the same requirements at 2 SD above the negative panel was also performed. Fisher's exact p-values are shown above each table. Post dose 1 and post dose 2 samples are combined in this analysis.

Post-hoc unmatched analyses comparing proportion of controls anti-PEG IgE positive among Moderna vs Pfizer-BioNTech recipients: b vs d, p=.03; c vs e, p=.003

Table 3. Comparison of Anti-PEG IgG and IgM Positivity in Case-patients and Controls^a

Antibody and category	DCBA Assay			PPBA Assay		
	Case-patients n (%)	Controls n (%)	P-value	Case-patients n (%)	Controls n (%)	P-value
Anti-PEG IgG						
Recipients of either vaccine			0.01*			0.45
Anti-PEG IgG positive	4 (20)	31 (52)		9 (45)	33 (55)	
Anti-PEG IgG negative	16 (80)	29 (48)		11 (55)	27 (45)	
Total	20	60		20	60	
Moderna vaccine recipients			0.003*			0.16
Anti-PEG IgG positive	1 (10)	20 (67) ^b		4 (40)	20 (67) ^c	
Anti-PEG IgG negative	9 (90)	10 (33) ^b		6 (60)	10 (33) ^c	
Total	10	30		10	30	
Pfizer-BioNTech vaccine recipients			>.99			0.73
Anti-PEG IgG positive	3 (30)	11 (37) ^d		5 (50)	13 (43) ^e	
Anti-PEG IgG negative	7 (70)	19 (63) ^d		5 (50)	17 (57) ^e	
Total	10	30		10	30	
Anti-PEG IgM						
Recipients of either vaccine			0.44			0.62
Anti-PEG IgM positive	1 (5)	8 (13)		10 (50)	26 (43)	
Anti-PEG IgM negative	19 (95)	52 (87)		10 (50)	34 (57)	
Total	20	60		20	60	
Moderna vaccine recipients			0.17			0.16
Anti-PEG IgM positive	0 (0)	8 (27) ^f		4 (40)	20 (67) ^g	
Anti-PEG IgM negative	10 (100)	22 (73) ^f		6 (60)	10 (33) ^g	
Total	10	30		10	30	
Pfizer-BioNTech vaccine recipients			0.25			0.04*
Anti-PEG IgM positive	1 (10)	0 (0) ^h		6 (60)	6 (20) ^j	
Anti-PEG IgM negative	9 (90)	30 (100) ^h		4 (40)	24 (80) ^j	
Total	10	30		10	30	

^aPositivity is based on a titer of $\geq 1:20$ for dual bead cytometric assay (DCBA) and greater than 3SD threshold for the PEG polystyrene bead assay (PPBA). The Fisher's exact test p-values are shown above each table. Significant results of $p < 0.05$ are followed by an asterisk.

Post-hoc unmatched analyses comparing proportion of controls anti-PEG IgG positive (or anti-PEG IgM positive) among Moderna vs Pfizer-BioNTech recipients: b vs d, $p=.04$; c vs e, $p=.12$; f vs h, $p=.005$, g vs j, $p=.001$